ClinicalTrials.gg
RecruitingNCT07024966PT-SILAOXUpdated Aug 27, 2025

Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress

An interventional study of Pterostilbene-silybin-nicotinamide riboside and Control Group in Oxidative Stress, Physical Activity and Antioxidant Effect, sponsored by Fundació Eurecat. Recruiting at 1 site in Spain. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Fundació Eurecat · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.

Planned enrollment
514th of 539
14 · median 80
Started
2025
with 76 others
No phase
515 of 597
125 open now
Primary completion
2025-11
later than 57 of 183 live
Registered
485th of 597
by date

Among the 597 studies in Motor Activity with a site in Spain, this one is the 514th largest by planned enrollment of the 539 interventional ones that give a count, is one of 77 that started in 2025, is one of 515 with no phase, reaches primary completion later than 57 of the 183 other live ones, and was the 485th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 597 studies in Motor Activity with a site in Spain, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels.

Secondary objectives include evaluating the effects on oxidative DNA damage (8-OHdG), lipid peroxidation (F2-isoprostanes), total antioxidant capacity (FRAP assay), glutathione ratio (GSH/GSSG), antioxidant enzyme activity (SOD, CAT, GPx), inflammatory markers (hsCRP, MCP-1, IL-6), muscle damage markers (LDH, CK), cortisol levels, renal function (creatinine), and gene expression patterns through transcriptomic analysis.

The study will include 14 healthy male participants in a randomized, tripple-blind, placebo-controlled, crossover design. Each participant will receive both the ccPT-SIL-NR supplement and placebo for 14 days each, separated by a washout period of at least one week. A high-intensity exercise test will be performed at the end of each supplementation period. Total study duration per participant will be a minimum of 6 weeks.

Read the detailed description

This study aims to evaluate the effect of a nutritional supplement combining pterostilbene, silybin, and nicotinamide riboside on oxidative stress induced by high-intensity exercise. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species and the body's ability to counteract their harmful effects. High-intensity physical activity is known to increase oxidative stress, potentially leading to cellular damage and inflammation. The supplement under investigation has shown antioxidant properties in preclinical models, and this trial seeks to explore its efficacy in humans. The trial is a randomized, triple-blind, placebo-controlled, and crossover study. Fourteen healthy, physically active men aged 18-50 will be recruited. Each participant will take either the supplement or placebo twice daily for 14 days, followed by a treadmill exercise session at 80% of their VO₂ max. After a washout period, participants will switch treatments and repeat the protocol. Blood and urine samples will be collected both at baseline (prior to supplement intake and without any physical activity) and after the exercise test to evaluate markers of oxidative stress, inflammation, muscle damage, and antioxidant capacity. The main outcome is the change in plasma levels of malondialdehyde (MDA). Secondary outcomes include urinary 8-OHdG and F2-isoprostanes, antioxidant enzyme activities, cortisol levels, and gene expression profiles. This study will help to determine whether the supplement can mitigate exercise-induced oxidative stress and support recovery in recreational athletes.

Participants will attend seven in-person visits:

  • V0; week 0 (Screening): Informed consent, eligibility check, medical history, anthropometry.
  • V1; week 1 (Baseline 1): Pre-intervention samples collection, supplement/placebo dispensation.
  • V2; week 1: Exercise test to determine VO₂ max.
  • V3; week 3: First treadmill session after 14 days of intervention with the supplement or placebo, blood draw.
  • V4; week 3: Urine sample drop-off post-exercise (0-3h and 3-24h).
  • V5; week 4 (Baseline 2): Pre-second intervention samples, crossover begins.
  • V6; week 6: Second treadmill session, blood draw.
  • V7; week 6: Final urine collection post-exercise (0-3h and 3-24h)..
03

Conditions studied

  • Oxidative Stress
  • Physical Activity
  • Antioxidant Effect

Browse trials for

Keywords

  • Oxidative Stress
  • High-intensity exercise
  • Pterostilbene
  • Antioxidant supplement
  • Nutraceutical
  • Crossover trial
  • Exercise recovery
  • Nutritional intervention
  • Polyphenols
  • Cocrystal
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants between 18 and 50 years of age who are amateur runners.
  • Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).*
  • Self-report being able to continuously run for 45 minutes at high intensity without difficulty.
  • Provide signed prior to participation in the study.
  • Able to read, write, and speak either Catalan or Spanish.

    • High level of physical activity according to the IPAQ: vigorous physical activity (such as running) on at least 3 days per week, with a total energy expenditure ≥1500 MET-min/week.

MET value for vigorous activity = 8 × minutes × days per week.

Exclusion criteria

Exclusion Criteria:

  • (BMI) ≤ 18 kg/m² or ≥ 30 kg/m².
  • Presence of chronic diseases associated with increased oxidative stress, such as diabetes, hypertension, (COPD), or neurodegenerative diseases.
  • Personal history of cardiovascular disease, including myocardial infarction, angina pectoris, stroke, or peripheral artery disease.
  • Use of antibiotics within 30 days prior to study entry.
  • Use of medications or vitamin supplements that may interfere with the study supplement and exceed 100% of the recommended daily intake within 30 days prior to the start of the study.
  • Use of polyphenol supplements, herbal extracts, or phytotherapeutic products that may interfere with the study treatment within 30 days prior to study start.
  • Alcohol consumption of 4 or more Standard Drink Units (SDUs) per day or 28 SDUs per week.*

    *One SDU is defined as 10 grams of alcohol. This corresponds approximately to: 1 glass of wine (120 mL), 1 beer (330 mL), or 1 small spirit (25 mL); 2 SDUs correspond to 1 glass of brandy or liqueur (55 mL), 1 whiskey (70 mL), or a mixed drink (75 mL).

  • Active smoker.
  • Unintentional weight loss of more than 3 kg in the past 3 months.
  • Known food allergies and/or intolerances related to the study products.
  • Presence of anemia.
  • Presence of chronic gastrointestinal diseases* or cancer.**

    *Chronic gastrointestinal diseases include those in an active phase that may interfere with nutrient absorption. Common examples include gastritis, hiatal hernia, Crohn's disease, celiac disease, irritable bowel syndrome, diverticulitis, diverticulosis, chronic constipation, and ulcerative colitis.

    **Individuals with a history of cancer may be included only if they are in complete remission at the start of the study.

  • Participation in another drug clinical trial or nutritional intervention study within 30 days prior to study inclusion.
  • Inability to follow the study guidelines.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants treated with Microcrystalline Cellulose for 14 days

    Dietary Supplement: Control Group

  • Experimental
    ccPT-SIL-NR Group

    Participants treated with pterostilbene, silybin, and nicotinamide riboside for 14 days

    Dietary Supplement: Pterostilbene-silybin-nicotinamide riboside

Interventions

  • Dietary supplementPterostilbene-silybin-nicotinamide riboside

    Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.

  • Dietary supplementControl Group

    Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.

06

What researchers measure

Primary outcomes

  1. Malondialdehyde (MDA) plasma levels

    Plasma MDA levels will be measured using commercial ELISA kits

    Time frame: At week 1, week 3, week 4 and week 6.

Secondary outcomes

  1. Age

    The age of the volunteers will be recorded in the case report form.

    Time frame: At week 0 (pre-selection visit)

  2. Height (cm)

    Height measured with standardized method

    Time frame: At week 0 (pre-selection visit)

  3. Body Weight (Kg)

    Weight measured using the InBody 970 device

    Time frame: At week 0 (pre-selection visit)

  4. Body Mass Index (BMI) (Kg/m^2)

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: At week0 (pre-selection visit)

  5. Urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels

    Urine 8-OHdG levels will be measured using commercial ELISA kits

    Time frame: At week 1, week 3, week 4 and week 6.

  6. Urine F2-isoprostanes levels

    Urine F2-isoprostanes levels will be measured using commercial ELISA kits

    Time frame: At week 1, week 3, week 4 and week 6.

  7. Plasma antioxidant capacity

    Plasma antioxidant capacity will be measured by the Ferric Reducing Antioxidant Power assay using ELISA kits.

    Time frame: At week 1, week 3, week 4 and week 6.

  8. Erythrocyte Redox Status (GSH/GSSG Ratio)

    The ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) will be measured in erythrocytes using commercial ELISA kits.

    Time frame: At week 1, week 3, week 4 and week 6.

  9. Superoxide Dismutase (SOD) Activity

    Serum levels of superoxide dismutase (SOD) activity will be measured using a commercial ELISA kit.

    Time frame: At week 1, week 3, week 4 and week 6.

  10. Catalase (CAT) Activity

    Serum catalase (CAT) activity will be measured using a commercial ELISA kit.

    Time frame: At week 1, week 3, week 4 and week 6.

  11. Glutathione Peroxidase (GPx) Activity

    Serum levels of glutathione peroxidase (GPx) activity will be measured using a commercial ELISA kit.

    Time frame: At week 1, week 3, week 4 and week 6.

  12. Serum High-Sensitivity C-Reactive Protein (hs-CRP) Levels

    Serum levels of high-sensitivity C-reactive protein (hs-CRP) will be measured using turbidimetric methods.

    Time frame: At week 1, week 3, week 4 and week 6.

  13. Plasma Monocyte Chemoattractant Protein-1 (MCP-1) Levels

    Plasma levels of monocyte chemoattractant protein-1 (MCP-1) will be measured using a commercial multiplex Cytometric Bead Array kit.

    Time frame: At week 1, week 3, week 4 and week 6.

  14. Plasma Interleukin-6 (IL-6) Levels

    Plasma levels of interleukin-6 (IL-6) will be measured using a commercial multiplex Cytometric Bead Array kit.

    Time frame: At week 1, week 3, week 4 and week 6.

  15. Plasma Lactate Dehydrogenase (LDH) Levels

    Plasma levels of lactate dehydrogenase (LDH) will be measured using commercial ELISA kits.

    Time frame: At week 1, week 3, week 4 and week 6.

  16. Plasma Creatine Kinase (CK) Levels

    Plasma levels of creatine kinase (CK) will be measured using commercial ELISA kits

    Time frame: At week 1, week 3, week 4 and week 6.

  17. Serum Cortisol Levels

    Serum cortisol levels will be determined using electrochemiluminescence methods.

    Time frame: At week 1, week 3, week 4 and week 6.

  18. Urinary Creatinine Levels

    Urinary creatinine levels will be measured using a commercial ELISA kit

    Time frame: At week 1, week 3, week 4 and week 6.

  19. Maximal Oxygen Uptake (VO₂ max)

    VO₂ max. be assessed through a graded exercise test. This data will be used to calibrate subsequent treadmill sessions at 80% of each participant's VO₂ max.

    Time frame: At week 1.

  20. Heart Rate, Treadmill Speed and Incline

    Heart rate, treadmill speed, and incline at the intensity of 80% of each participant's VO₂ max. will be recorded in the case report form.

    Time frame: At week 1.

  21. Physical Activity Level (Questionnaire-Based)

    Physical activity level will be assessed using the "Quick Physical Activity Classifier" questionnaire, adapted from the PEFS Guide of the Catalan Government.

    Time frame: At week 0, week 1, week 3, week 4 and week 6.

  22. Whole Blood Transcriptomic Profile (RNA-seq)

    Gene expression will be analyzed in whole blood samples preserved in PAXgene Blood RNA tubes.

    Time frame: At week 1, week 3, week 4 and week 6.

  23. Concomitant medication

    The use of any concomitant medication will be recorded through participant-reported entries in the case report form.

    Time frame: At week 0, week 1, week 3, week 4 and week 6.

  24. Heart Rate

    Heart rate will be measured using the Omron HEM-907 monitor.

    Time frame: At week 0, week 1, week 3, week 4 and week 6.

  25. Systolic Blood Pressure

    Systolic Blood Pressure will be measured using the Omron HEM-907 monitor.

    Time frame: At week 0, week 1, week 3, week 4 and week 6.

  26. Diastolic Blood Pressure

    Diastolic Blood Pressure will be measured using the Omron HEM-907 monitor.

    Time frame: At week 0, week 1, week 3, week 4 and week6.

  27. Use of Dietary Supplements

    Dietary supplements consumed during the study will be recorded in the case report form.

    Time frame: At week 0, week 1, week 3, week 4 and week 6.

  28. Intervention Compliance (Supplement Intake Adherence)

    Compliance with the intervention will be assessed indirectly by calculating the ratio between the number of supplement sachets theoretically assigned and the number actually consumed.

    Time frame: At week 3 and week 6.

  29. Adverse events

    Possible adverse events derived from taking study's products will be recorded in the case report form

    Time frame: At week 3 and week 6.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2025, 3 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 3 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024966
Lead sponsor
Fundació Eurecat
Collaborators
Circe, S.L.
Responsible party
Antoni Caimari (Director of the of the Biotechnology Area, Fundació Eurecat) — Principal investigator
First posted
Jun 17, 2025
Start date
Aug 1, 2025
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Aug 27, 2025

Study contacts

Antoni Caimari, PhD
Contact
antoni.caimari@eurecat.org
+34 977 300 431 ext. 4814
Anna Crescenti, PhD
Contact
anna.crescenti@eurecat.org
+34 977 300 431 ext. 4814
Antoni Caimari, PhD
principal investigator · Fundació Eurecat

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion